Registered title, quoted from ClinicalTrials.gov
Impacted Tooth Management and Osteoradionecrosis Risk in NPC
An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Guangxi Medical University; 6 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 7
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
- Study siteAffiliated Hospital of Guilin Medical University桂林医学院附属医院GuilinHospital page
- Study siteAffiliated Hospital of Youjiang Medical University右江民族医学院附属医院ZhongshanHospital page
- Study siteFourth Affiliated Hospital of Guangxi Medical University广西医科大学第四附属医院LiuzhouHospital page
- Study siteLiuzhou People's Hospital柳州市人民医院LiuzhouHospital page
- Study sitePeople's Hospital of Guangxi Zhuang Autonomous Region广西壮族自治区人民医院NanningHospital page
- Study siteWuzhou Red Cross Hospital梧州市红十字会医院WuzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07764887, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically confirmed non-keratinizing nasopharyngeal carcinoma, including differentiated or undifferentiated subtype (WHO type II or III).
Inclusion criterion 3
Newly diagnosed, previously untreated nasopharyngeal carcinoma with stage T1-4N0-3M0 according to the 9th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system.
Inclusion criterion 4
History of active tuberculosis more than 1 year previously without documented completion of standard anti-tuberculosis treatment.
Exclusion criterion 21
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Inclusion criterion 1
History of active malignancy or other malignant tumors diagnosed within the previous 5 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ.
Exclusion criterion 6
Positive hepatitis B surface antigen (HBsAg) with hepatitis B virus DNA >1,000 copies/mL.
Exclusion criterion 17
Active hepatitis C virus infection (positive HCV RNA).
Exclusion criterion 18
Human immunodeficiency virus (HIV) infection or diagnosis of acquired immunodeficiency syndrome (AIDS).
Exclusion criterion 19
Active tuberculosis within the previous 1 year.
Exclusion criterion 20
Pregnant or breastfeeding women.
Exclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07764887, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Age 18-75 years, regardless of sex.
- Histologically confirmed non-keratinizing nasopharyngeal carcinoma, including differentiated or undifferentiated subtype (WHO type II or III).
- Newly diagnosed, previously untreated nasopharyngeal carcinoma with stage T1-4N0-3M0 according to the 9th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system.
- Presence of permanent dentition with at least one impacted third molar.
- Adequate bone marrow function, defined as white blood cell count ≥4.0 × 10⁹/L, platelet count ≥100 × 10⁹/L, and hemoglobin ≥90 g/L.
- Adequate hepatic function, defined as alanine aminotransferase and aspartate aminotransferase ≤2.5 × the upper limit of normal (ULN), and total bilirubin ≤1.5 × ULN.
- Adequate renal function, defined as blood urea nitrogen and serum creatinine ≤1.5 × ULN, or creatinine clearance ≥60 mL/min.
- Coagulation function within normal limits.
- Written informed consent provided, with willingness and ability to comply with study visits, treatment plans, laboratory assessments, and other study procedures.
Exclusion Criteria:
- Histopathological diagnosis other than WHO type II or III nasopharyngeal carcinoma.
- Impacted third molars with recurrent pericoronitis or inflammation due to incomplete eruption.
- Fully erupted third molars with dental caries involving the pulp.
- Impacted third molars with radiographic evidence of periapical or periodontal inflammation.
- Third molars completely impacted within the jawbone.
- History of active malignancy or other malignant tumors diagnosed within the previous 5 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ.
- Previous chemotherapy, surgery (except diagnostic procedures), radiotherapy, or other antitumor treatment for nasopharyngeal carcinoma or cervical lesions.
- Patients receiving palliative treatment.
- Pregnant or breastfeeding women.
- Severe uncontrolled cardiovascular or cerebrovascular diseases.
- Severe hepatic or renal dysfunction.
- Uncontrolled diabetes mellitus.
- Severe osteoporosis, medication-related osteonecrosis/osteomyelitis, or chronic diseases requiring long-term systemic corticosteroid therapy.
- Other severe chronic debilitating diseases that may increase study risk or affect study compliance.
- History of drug abuse or alcohol dependence.
- Uncontrolled psychiatric disorders or inability to provide legally valid informed consent.
- Positive hepatitis B surface antigen (HBsAg) with hepatitis B virus DNA >1,000 copies/mL.
- Active hepatitis C virus infection (positive HCV RNA).
- Human immunodeficiency virus (HIV) infection or diagnosis of acquired immunodeficiency syndrome (AIDS).
- Active tuberculosis within the previous 1 year.
- History of active tuberculosis more than 1 year previously without documented completion of standard anti-tuberculosis treatment.
- Any other medical, psychological, social, or laboratory condition that, in the investigator's judgment, may compromise participant safety, interfere with study procedures, affect protocol compliance, or result in premature withdrawal from the study.
- Refusal or inability to provide written informed consent.
Quoted from ClinicalTrials.gov, NCT07764887, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07764887, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.